Table 1.
Baseline characteristics and discharge medications.
| Variables | Group A (Age, ≥65 Years, n = 2253) |
Group B (Age, <65 Years, n = 2260) |
||||
|---|---|---|---|---|---|---|
| Group A1 Early Invasive (n = 1612) |
Group A2 Delayed Invasive (n = 641) |
p Value | Group B1 Early Invasive (n = 1688) |
Group B2 Delayed Invasive (n = 572) |
p Value |
|
| Male, n (%) | 927 (57.5) | 371 (57.9) | 0.872 | 1476 (87.4) | 513 (89.7) | 0.153 |
| Age, years | 74.3 ± 5.8 | 75.0 ± 5.9 | 0.007 | 54.4 ± 7.3 | 54.5 ± 7.2 | 0.760 |
| LVEF, % | 53.2 ± 10.6 | 51.6 ± 12.3 | 0.005 | 55.9 ± 9.4 | 55.1 ± 10.9 | 0.149 |
| BMI, kg/m2 | 23.2 ± 3.1 | 23.5 ± 3.3 | 0.048 | 25.0 ± 3.2 | 24.8 ± 3.1 | 0.120 |
| SBP, mmHg | 133.5 ± 26.4 | 135.4 ± 25.8 | <0.001 | 137.0 ± 25.8 | 139.2 ± 25.8 | 0.087 |
| DBP, mmHg | 80.4 ± 15.7 | 81.3 ± 14.8 | 0.038 | 83.9 ± 15.8 | 83.8 ± 15.1 | 0.874 |
| Symptom-to-door time, h | 8.0 (3.0–28.6) | 8.8 (2.7–45.3) | 0.054 | 5.8 (2.0–19.3) | 4.5 (1.6–23.9) | 0.181 |
| Door-to-balloon time, h | 6.0 (2.9–16.1) | 46.4 (31.1–71.6) | <0.001 | 6.9 (3.0–16.1) | 43.2 (29.8–58.6) | <0.001 |
| Killip class 3 | 181 (11.2) | 98 (15.3) | 0.011 | 65 (3.9) | 34 (5.9) | 0.044 |
| Hypertension, n (%) | 1050 (65.1) | 427 (66.6) | 0.505 | 662 (39.2) | 243 (42.5) | 0.183 |
| Diabetes mellitus, n (%) | 567 (35.2) | 227 (35.4) | 0.914 | 408 (24.2) | 154 (26.9) | 0.198 |
| Dyslipidemia, n (%) | 154 (9.6) | 83 (12.9) | 0.022 | 225 (13.3) | 92 (16.1) | 0.109 |
| Previous MI, n (%) | 136 (8.4) | 48 (7.5) | 0.496 | 73 (4.3) | 388 (6.6) | 0.033 |
| Previous PCI, n (%) | 112 (6.9) | 33 (5.1) | 0.128 | 66 (3.9) | 34 (5.9) | 0.046 |
| Previous CABG, n (%) | 6 (0.4) | 3 (0.5) | 0.720 | 2 (0.1) | 1 (0.2) | 0.749 |
| Previous HF, n (%) | 27 (1.7) | 15 (2.3) | 0.302 | 9 (0.5) | 6 (1.0) | 0.230 |
| Previous stroke, n (%) | 124 (7.7) | 57 (8.9) | 0.346 | 60 (3.6) | 23 (4.0) | 0.608 |
| Current smokers, n (%) | 324 (20.1) | 102 (15.9) | 0.023 | 921 (54.6) | 309 (54.0) | 0.846 |
| Peak CK-MB, mg/dL | 20.9 (6.4–78.6) | 13.9 (5.0–42.6) | <0.001 | 29.0 (7.2–99.0) | 15.6 (4.6–56.7) | <0.001 |
| Peak Troponin-I, ng/mL | 10.6 (2.1–22.1) | 4.7 (1.1–18.9) | <0.001 | 14.3 (2.8–23.1) | 5.4 (1.0–21.1) | <0.001 |
| Blood glucose, mg/dL | 158.6 ± 72.7 | 162.1 ± 80.2 | 0.338 | 153.6 ± 73.4 | 158.9 ± 79.6 | 0.157 |
| Hs-CRP (mg/dL) | 1.53 ± 3.24 | 1.78 ± 7.72 | 0.440 | 1.07 ± 2.50 | 1.11 ± 2.10 | 0.687 |
| Serum creatinine (mg/L) | 1.12 ± 1.15 | 1.26 ± 1.34 | 0.023 | 1.04 ± 1.27 | 1.21 ± 1.73 | 0.034 |
| eGFR < 60 mL/min/1.73 m2, n (%) | 570 (35.4) | 269 (42.0) | 0.003 | 193 (11.4) | 86 (15.0) | 0.027 |
| Total cholesterol, mg/dL | 171.9 ± 43.3 | 171.7 ± 44.1 | 0.900 | 188.5 ± 43.1 | 185.3 ± 41.9 | 0.117 |
| Triglyceride, mg/L | 111.7 ± 71.8 | 112.8 ± 82.7 | 0.771 | 152.7 ± 96.3 | 156.2 ± 94.3 | 0.523 |
| HDL cholesterol, mg/L | 43.1 ± 11.4 | 44.5 ± 82.7 | 0.013 | 42.1 ± 10.8 | 42.2 ± 10.6 | 0.913 |
| LDL cholesterol, mg/L | 108.7 ± 34.7 | 106.0 ± 35.3 | 0.101 | 120.2 ± 36.8 | 116.9 ± 35.3 | 0.053 |
| GRACE risk score | 151.2 ± 34.5 | 154.4 ± 36.7 | 0.058 | 105.8 ± 28.4 | 106.5 ± 32.3 | 0.676 |
| >140, n (%) | 979 (60.7) | 390 (60.8) | 0.961 | 171 (10.1) | 81 (14.2) | 0.011 |
| Atrial fibrillation, n (%) | 93 (5.8) | 44 (6.9) | 0.329 | 26 (1.5) | 13 (2.3) | 0.265 |
| ST-depression, n (%) | 392 (24.3) | 157 (24.5) | 0.930 | 334 (19.8) | 103 (18.0) | 0.352 |
| T-wave inversion, n (%) | 370 (23.0) | 155 (24.2) | 0.534 | 291 (17.2) | 119 (20.8) | 0.060 |
| Discharge medications, n (%) | ||||||
| Aspirin, n (%) | 1600 (99.3) | 635 (99.1) | 0.645 | 1678 (99.4) | 568 (99.3) | 0.778 |
| Clopidogrel, n (%) | 1251 (77.6) | 540 (84.2) | <0.001 | 1065 (63.1) | 406 (71.0) | 0.001 |
| Ticagrelor, n (%) | 283 (17.6) | 77 (12.0) | 0.001 | 361 (21.4) | 109 (19.1) | 0.257 |
| Prasugrel, n (%) | 78 (4.8) | 24 (3.7) | 0.106 | 262 (15.5) | 57 (10.0) | 0.001 |
| BBs, n (%) | 1354 (84.0) | 542 (84.6) | 0.742 | 1491 (88.3) | 485 (84.8) | 0.029 |
| ACEIs or ARBs, n (%) | 1361 (84.4) | 506 (78.9) | 0.002 | 1423 (84.3) | 462 (80.8) | 0.051 |
| Statin, n (%) | 1534 (95.2) | 601 (93.8) | 0.178 | 1631 (96.6) | 541 (94.6) | 0.033 |
| Anticoagulant, n (%) | 50 (3.1) | 25 (3.9) | 0.362 | 11 (0.7) | 10 (1.7) | 0.024 |
| Infarct-related artery | ||||||
| Left main, n (%) | 50 (3.1) | 25 (3.9) | 0.362 | 33 (2.0) | 23 (4.0) | 0.008 |
| LAD, n (%) | 684 (42.4) | 286 (44.6) | 0.346 | 723 (42.8) | 238 (41.6) | 0.625 |
| LCx, n (%) | 400 (24.8) | 141 (22.0) | 0.172 | 459 (27.2) | 150 (26.2) | 0.663 |
| RCA, n (%) | 478 (29.7) | 189 (29.5) | 0.959 | 473 (28.0) | 161 (28.1) | 0.957 |
| Multivessel disease, n (%) | 971 (60.2) | 423 (66.0) | 0.011 | 811 (48.0) | 300 (52.4) | 0.073 |
| ACC/AHA type B2/C lesions | 1373 (85.2) | 544 (84.9) | 0.854 | 1413 (83.7) | 467 (81.6) | 0.271 |
| Pre-PCI TIMI flow grade 0/1 | 633 (39.3) | 199 (31.0) | <0.001 | 760 (45.0) | 177 (30.9) | <0.001 |
| GP IIb/IIIa inhibitor | 133 (8.3) | 43 (6.7) | 0.258 | 174 (10.3) | 41 (7.2) | 0.026 |
| Transradial approach | 781 (48.4) | 309 (48.2) | 0.926 | 959 (56.8) | 292 (51.0) | 0.017 |
| IVUS/OCT, n (%) | 346 (21.5) | 174 (27.1) | 0.004 | 421 (24.9) | 202 (35.3) | <0.001 |
| FFR, n (%) | 27 (1.7) | 23 (3.6) | 0.010 | 33 (2.0) | 24 (4.2) | 0.005 |
| Drug-eluting stents a | ||||||
| ZES, n (%) | 374 (23.2) | 155 (24.2) | 0.621 | 419 (24.8) | 142 (24.8) | 0.999 |
| EES, n (%) | 860 (53.3) | 332 (51.8) | 0.504 | 878 (52.0) | 294 (51.4) | 0.809 |
| BES, n (%) | 326 (20.2) | 144 (22.5) | 0.237 | 340 (20.1) | 125 (21.9) | 0.402 |
| Others, n (%) | 52 (3.2) | 10 (1.6) | 0.032 | 51 (3.0) | 11 (1.9) | 0.184 |
| Stent diameter (mm) | 3.04 ± 0.40 | 3.03 ± 0.41 | 0.531 | 3.12 ± 0.43 | 3.10 ± 0.44 | 0.196 |
| Stent length (mm) | 30.2 ± 14.4 | 31.1 ± 14.9 | 0.205 | 28.6 ± 13.2 | 29.8 ± 14.5 | 0.074 |
| Number of stents | 1.22 ± 0.46 | 1.26 ± 0.50 | 0.044 | 1.17 ± 0.42 | 1.22 ± 0.47 | 0.030 |
Values are means ± standard deviation or median (interquartile range) or numbers and percentages. The p values for continuous data were obtained from the unpaired t-test. The p values for categorical data from chi-square or Fisher’s exact test. LVEF, left ventricular ejection fraction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; HF, heart failure; CK-MB, creatine kinase myocardial band; Hs-CRP, high sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; GRACE, Global Registry of Acute Coronary Events; BBs, ß-blockers; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; LAD, left anterior descending artery; LCx, left circumflex artery; RCA, right coronary artery; ACC/AHA, American College of Cardiology/American Heart Association; TIMI, thrombolysis in myocardial infarction; GP, glycoprotein; IVUS, intravascular ultrasound; OCT, optical coherence tomography; FFR, fractional flow reserve; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting stent. a Drug-eluting stents were composed of ZES (Resolute Integrity stent; Medtronic, Inc., Minneapolis, MN), EES (Xience Prime stent, Abbott Vascular, Santa Clara, CA; or Promus Element stent, Boston Scientific, Natick, MA), and BES (BioMatrix Flex stent, Biosensors International, Morges, Switzerland; or Nobori stent, Terumo Corporation, Tokyo, Japan).